Tag - Korean biosimilar drugs on way to global expansion

Korean biosimilar drugs on way to global expansion

Led by Celltrion and Samsung Bioepis, South Korea’s biopharmaceutical companies are making strides in the emerging drug category of biosimilars — lower-cost replications of the world’s top-selling biologic drugs that have lost patent protection. Drawing much spotlight this week, Samsung Bioepis, Samsung Group’s biopharmaceutical affiliate, said Sunday that Benepali, its biosimilar copy of Amgen’s blockbuster rheumatoid arthritis treatment Enbrel (etanercept) has been granted sales approval in Europe. A day later, Celltrion announced that the U.S. Food and Drug Administration is scheduled [...]

Read more...